2022, doi: 10.1002/cpt.2430
Use 29-31 gauge insulin syringes for subcutaneous injections
On average, people taking injectable Semaglutide with Henry lost ~18% of their body weight in a year.1 Everyone is different and your results will vary depending on your medication, dosing, medical history, and other factors like diet and exercise
If youre currently taking or considering a GLP-1 medication, understanding these potential long-term risks, especially those affecting bone health, could be crucial for protecting your overall wellness for years to come
Course Highlights Discover how combining lifestyle modifications with GLP-1 receptor agonists can improve weight loss, glycemic control, and overall cardiometabolic health Examine the science behind GLP-1 receptor agonists, from their effects on insulin secretion and appetite regulation to next-generation agents like tirzepatide and orforglipron Learn best practices for patient education, dosing strategies, and interprofessional collaboration while addressing contraindications, adverse effects, and compounding warnings Introduction Obesity is a chronic and prevalent condition that impacts health, contributing to higher rates of morbidity and mortality
Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]
